(Total Views: 561)
Posted On: 03/30/2021 10:20:42 AM
Post# of 148899
Re: onestepahead #84695
“Dr Jay L had wanted higher doses from almost day one”
Yes - huge props to Dr Jay, I recall him being very vocal about this. I have two questions:
1.) Why did Cytodyn not manage the FDA to require more doses? We knew it was a good idea before the trial started. I don’t buy this is the FDA’s fault - we could have proposed another arm to test dosing.
2.) Where was this information when the initial CD12 results were reported? If it took three weeks to crunch these numbers we need to fire our statistician.
As CDiddy says, we need to stop acting like rookies. We need to seriously improve everything from initial trial design, to trial management, to statistical analysis, to public relations. One has to wonder how these issues will be managed with the other indications. If that means a management change then so be it.
Read More: https://investorshangout.com/post/newpost/605...z6qbWAY0h1
Yes - huge props to Dr Jay, I recall him being very vocal about this. I have two questions:
1.) Why did Cytodyn not manage the FDA to require more doses? We knew it was a good idea before the trial started. I don’t buy this is the FDA’s fault - we could have proposed another arm to test dosing.
2.) Where was this information when the initial CD12 results were reported? If it took three weeks to crunch these numbers we need to fire our statistician.
As CDiddy says, we need to stop acting like rookies. We need to seriously improve everything from initial trial design, to trial management, to statistical analysis, to public relations. One has to wonder how these issues will be managed with the other indications. If that means a management change then so be it.
Read More: https://investorshangout.com/post/newpost/605...z6qbWAY0h1
(9)
(0)Scroll down for more posts ▼
